Canaccord Genuity initiated coverage of Tonix Pharmaceuticals Holding Corp (TNXP) at Buy on October 26, 2026.
The past 90 days include one active firm, with one rating the stock bullish. The consensus price targets from eight analysts as of October 30, 2026, have a mean of $39.10, a median of $31.11 and a range of $18.18 to $68.25.
For Q4 FY2026, analysts expect EPS of -$2.41 and revenue of $20.12 million. The next earnings report is scheduled for November 9, 2026 (confirmed).
